Development of NMDAR Antagonists with Reduced Neurotoxic Side Effects: a Study on GK11

• Delphine Vandame ,

  Contributed equally to this work with: Delphine Vandame, Lauriane Ulmann

  Affiliation INSERM, U1051, Institut de Neurosciences de Montpellier, Montpellier, France

  ⨯
• Lauriane Ulmann ,

  Contributed equally to this work with: Delphine Vandame, Lauriane Ulmann

  Affiliations CNRS, UMR 5203, Institut de Génomique Fonctionnelle, Labex ICST, Montpellier, France, INSERM, U661, Montpellier, France, Universités de Montpellier 1 & 2, UMR5203, Montpellier, France

  ⨯
• Marisa Teigell,

  Affiliation Neureva, CHU St Eloi, Montpellier, France

  ⨯
• Monica Prieto-Cappellini,

  Affiliation Neureva, CHU St Eloi, Montpellier, France

  ⨯
• Jacques Vignon,

  Affiliation INSERM, U1051, Institut de Neurosciences de Montpellier, Montpellier, France

  ⨯
• Alain Privat,

  Affiliation INSERM, U1051, Institut de Neurosciences de Montpellier, Montpellier, France

  ⨯
• Regino Perez-Polo,

  Affiliation Department of Biochemistry & Molecular Biology, UTMB, Galveston, Texas, United States of America

  ⨯
• Olivera Nesic ,

  ¶These authors also contributed equally to this work.

  Affiliations Department of Biochemistry & Molecular Biology, UTMB, Galveston, Texas, United States of America, Department of Medical Education, School of Medicine, El Paso, Texas, United States of America

  ⨯
• Helene Hirbec

  * E-mail: helene.hirbec@igf.cnrs.fr

  ¶These authors also contributed equally to this work.

  Affiliations INSERM, U1051, Institut de Neurosciences de Montpellier, Montpellier, France, CNRS, UMR 5203, Institut de Génomique Fonctionnelle, Labex ICST, Montpellier, France, INSERM, U661, Montpellier, France, Universités de Montpellier 1 & 2, UMR5203, Montpellier, France

  ⨯